Loading
Life sciences · Journal article
Materials Today · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Oncolytic viruses (OVs) are a promising class of cancer therapeutics, yet their clinical efficacy is frequently limited by inefficient viral entry into tumour cells. OV infection depends on receptor-mediated endocytosis initiated at the cell surface, but key viral entry receptors are often sequestered within intercellular junctions, restricting viral access. Here, we demonstrate that cold atmospheric plasma (CAP), a highly ionized gas enriched with reactive oxygen and nitrogen species, can directly and sustainably disrupt tumour cell junctions, thereby increasing the surface accessibility of viral entry receptors. This physical intervention markedly enhances receptor-mediated OV uptake, achieving over a threefold increase compared with untreated controls in B16F10 cell line. A similar enhancement in viral uptake was also observed in Hepa1-6, HCT116, and A549 cells. In a postoperative B16F10 tumour recurrence model, CAP-potentiated OV therapy outperformed monotherapy by suppressing tumour relapse and promoting antitumour immune responses.